UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
|
|
|
|
|
|
(Commission File No.) |
|
|
(IRS Employer Identification No.) |
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
|
|
(The Nasdaq Global Select Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
On May 26, 2022, the Company held its 2022 Annual Meeting of Stockholders and the following proposals were adopted:
|
1. |
Election of two Class I directors, Jerel Davis, Ph.D., and William M. Greenman, each to serve three-year terms through the 2025 annual meeting of stockholders and until a successor has been elected and qualified or until earlier resignation or removal: |
|
Nominees |
Shares For |
Shares Withheld |
Broker Non-Votes |
|
Jerel Davis, Ph.D. |
37,814,109 |
5,304,072 |
6,652,779 |
|
William M. Greenman |
37,587,076 |
5,531,105 |
6,652,779 |
|
2. |
Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: |
|
Shares For |
Shares Against |
Shares Abstaining |
|
49,603,452 |
165,881 |
1,627 |
|
3. |
Non-binding advisory approval on the compensation of our Named Executive Officers: |
|
Shares For |
Shares Against |
Shares Abstaining |
Broker Non-Votes |
|
41,713,487 |
1,383,009 |
21,685 |
6,652,779 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: June 2, 2022 |
|
|
|
Chinook Therapeutics, Inc. |
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Eric L. Dobmeier |
|
|
|
|
|
Eric L. Dobmeier |
|
|
|
|
|
President and Chief Executive Officer |